Skip Navigation


Nucleic Acids Research Advance Access originally published online on July 26, 2007
Nucleic Acids Research 2007 35(15):5141-5153; doi:10.1093/nar/gkm542
This Article
Right arrow Full Text Freely available
Right arrow Print PDF (5079K) Freely available
Right arrow Screen PDF (321K) Freely available
Right arrowOA All Versions of this Article:
35/15/5141    most recent
gkm542v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Henriet, S.
Right arrow Articles by Paillart, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henriet, S.
Right arrow Articles by Paillart, J.-C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2007, Vol. 35, No. 15 5141-5153
© 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


RNA

Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription

S. Henriet1, L. Sinck1, G. Bec1, R. J. Gorelick2, R. Marquet1 and J.-C. Paillart1,*

1Architecture et Réactivité de l’ARN, Université Louis Pasteur, CNRS, IBMC, 15 rue René Descartes, 67084, Strasbourg cedex, France and 2AIDS Vaccine Program, SAIC-Frederick Inc., NCI-Frederick, P.O. Box B, Frederick, MD, USA

*To whom correspondence should be addressed. Tel: +33 0 3 88 41 70 35; Fax: +33 0 3 88 60 22 18; Email: jc.paillart{at}ibmc.u-strasbg.fr Correspondence may also be addressed to Roland Marquet. Tel: +33 0 3 88 41 70 54; Fax: +33 0 3 88 60 22 18; Email: r.marquet{at}ibmc.u-strasbg.fr

Received June 7, 2007. Revised July 2, 2007. Accepted July 3, 2007.

HIV-1 Vif (viral infectivity factor) is associated with the assembly complexes and packaged at low level into the viral particles, and is essential for viral replication in non-permissive cells. Viral particles produced in the absence of Vif exhibit structural defects and are defective in the early steps of reverse transcription. Here, we show that Vif is able to anneal primer tRNALys3 to the viral RNA, to decrease pausing of reverse transcriptase during (–) strand strong-stop DNA synthesis, and to promote the first strand transfer. Vif also stimulates formation of loose HIV-1 genomic RNA dimers. These results indicate that Vif is a bona fide RNA chaperone. We next studied the effects of Vif in the presence of HIV-1 NCp, which is a well-established RNA chaperone. Vif inhibits NCp-mediated formation of tight RNA dimers and hybridization of tRNALys3, while it has little effects on NCp-mediated strand transfer and it collaborates with nucleocapsid (NC) to increase RT processivity. Thus, Vif might negatively regulate NC-assisted maturation of the RNA dimer and early steps of reverse transcription in the assembly complexes, but these inhibitory effects would be relieved after viral budding, thanks to the limited packaging of Vif in the virions.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
L. Houzet, Z. Morichaud, L. Didierlaurent, D. Muriaux, J.-L. Darlix, and M. Mougel
Nucleocapsid mutations turn HIV-1 into a DNA-containing virus
Nucleic Acids Res., April 1, 2008; 36(7): 2311 - 2319.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.